NaPi2b-PL2202 / ADC Therapeutics - LARVOL DELTA

Preclinical characterization of NaPi2b-PL2202, a novel exatecan-based antibody drug conjugate (EORTC-NCI-AACR 2024) - "Outside the FOLR1 high group, which is eligible for treatment with mirvetuximab soravtansine, 44.5% (n=37) cases were found with medium or high NaPi2b expression. NaPi2b-PL2202 demonstrated specific NaPi2b binding, efficient internalisation, potent in vivo anti-tumor activity in PDX models representing the indications of interest, and synergistic in vitro combination activity with olaparib. Importantly, medium or high NaPi2b expression was detected in a significant proportion of ovarian cancer patient derived samples which do not express high levels of FOLR1. Together, these observations support future clinical development of NaPi2b-PL2202 for the treatment of NaPi2b-expressing cancers as a single agent and in combination settings."

Preclinical • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1 • SLC34A2

Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b (AACR 2024) - "Together, these observations support future clinical development of NaPi2b-PL2202 for the treatment of NaPi2b-expressing cancers. 1- Bodyak N. D. et al., 2021 2- Valsenkova R. et al., 2021 3- Hakim S. A. et al., 2021"

Preclinical • Bladder Cancer • Endocrine Cancer • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • SLC34A2

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "ADC Therapeutics SA...today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024....'We’re excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting'...'We’re also looking forward to research from independent studies that highlight the potential of another investigational ADC, ADCT-601 targeting AXL.'"

Clinical data • P1 data • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Soft Tissue Sarcoma • Solid Tumor